First-Line EGFR TKI beim inoperablen NSCLC mit EGFR-aktivirenden Mutationen
| Quelle | Studie | Therapie | Patienten | Response | PFS | OS |
| Mok (1) | IPASS | Gefitinib | 132 | 71,2%* | 9,5M* | 21,6M |
| Chemotherapy | 129 | 47,3% | 6,3 M | 21,9M | ||
| Lee(2) | First-SIGNAL | Gefitinib | 22 | 84,6%* | 8,4M | 30,6M |
| Chemotherapy | 6 | 37,5 % | 6,7 M | 26,5 M | ||
| Maemondo(3) | NEJSG002 | Gefitinib | 114 | 73,7 %* | 10,8 M* | 30,5 M |
| Chemotherapy | 110 | 30,7% | 5,4 M | 23,6 M | ||
| Mitsudomi (4,5) | WJTOG 3405 | Gefitinib | 86 | 62,1%* | 9,2 M* | 35,5 M |
| Chemotherapy | 86 | 32,2 % | 6,3 M | 38,8 M | ||
| Zhou(6) | OPTIMAL (CTONG-0802) | Erlotinib | 82 | 82,9 % * | 13,1 M* | N/R |
| Chemotherapy | 72 | 36,1 % | 4,6 M | N/R | ||
| Rosell(7) | EURTAC | Erlotinib | 86 | 55 % * | 9,7 M* | N/R |
| Chemotherapy | 87 | 11% | 5,2 M | N/R | ||
| Yang (8) | LUX-Lung 3 | Afatinib | 230 | 56,1% | 11,1 M * | N/R |
| Chemotherapy | 115 | 22,6 % | 6,0 M | N/R |
N/R: nicht erreicht
*: signifikant
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
N Engl J Med 361(2009):947-957
2.) Han JY, et al:
First-SIGNAL: First-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.
J Clin Oncol 30(2012):1122-1128
3.) Maemondo M, et al:
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
N Engl J Med 362(2010):2380-2388
4.) Mitsudomi T, et al:
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial.
Lancet Oncol 11(2010):121-128
5.) Mitsudomi T, et al:
Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR).
J Clin Oncol 30(2012):485s, (suppl; abstr 7521)
6.) Zhou C, et al:
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study.
Lancet Oncol 12(2011):735-742
7.) Rosell R, et al:
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial.
Lancet Oncol 13(2012):239-246
8.) Yang JC-H, et al:
LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.
J Clin Oncol 30(2012):480s, (suppl; abstr LBA7500)
